In this interview conducted in anticipation of ELRIG’s Drug Discovery 2023 Conference, we spoke to Nick Clare, Vendor Strategy Work Group Lead for ELRIG, about what vendors can gain from attending ELRIG events, such as Drug Discovery 2023.
Harnessing ctDNA measurements for response assessment in metastatic castration resistant prostate cancer
A new editorial paper was published in Oncotarget’s Volume 15 on July 2, 2024, entitled, “Using early on-treatment circulating tumor DNA measurements as response assessment
July 18, 2024